Nautilus Biotechnology Inc (NAUT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nautilus Biotechnology Inc (NAUT) has a cash flow conversion efficiency ratio of -0.065x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.03 Million) by net assets ($169.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NAUT equity financing ratio to measure how much of total assets are equity-financed.
Nautilus Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Nautilus Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Nautilus Biotechnology Inc to evaluate the quality of earnings relative to operating cash generation.
Nautilus Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nautilus Biotechnology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Igis Value Plus Reit Co Ltd
KO:334890
|
N/A |
|
FinLab AG
F:A7A
|
0.013x |
|
Silk Logistics Holdings Ltd
AU:SLH
|
0.381x |
|
Climb Global Solutions
NASDAQ:CLMB
|
-0.102x |
|
Bohae Brewery
KO:000890
|
0.023x |
|
Gabelli Global Small and Mid Cap Value Closed Fund
NYSE:GGZ
|
0.000x |
|
Century Land Joint Stock Company
VN:CRE
|
-0.006x |
|
AMREP Corporation
NYSE:AXR
|
0.039x |
Annual Cash Flow Conversion Efficiency for Nautilus Biotechnology Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Nautilus Biotechnology Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Nautilus Biotechnology Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $208.73 Million | $-59.15 Million | -0.283x | -45.40% |
| 2023-12-31 | $265.35 Million | $-51.71 Million | -0.195x | -33.98% |
| 2022-12-31 | $314.92 Million | $-45.81 Million | -0.145x | -34.76% |
| 2021-12-31 | $363.58 Million | $-39.24 Million | -0.108x | -122.92% |
| 2020-12-31 | $-29.72 Million | $-14.00 Million | 0.471x | +187.98% |
| 2019-12-31 | $18.05 Million | $-9.66 Million | -0.535x | +98.88% |
| 2018-12-31 | $5.00 Million | $-238.30 Million | -47.660x | -- |
About Nautilus Biotechnology Inc
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical… Read more